AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05118100
Drug: Clearfil SE Bond
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
Trial: NCT00963924
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
Trial: NCT00524069
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03586674
Drug: Lipanthyl
RxNorm normalized name: Lipanthyl
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03309657
Drug: Ceftolozane/tazobactam
RxNorm normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
Trial: NCT01470651
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg - 250mg pills, taken each morning, for 14 weeks
Trial: NCT01470651
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pill, matched to look like active medication
Trial: NCT00496275
Drug: Zactima (ZD6474)
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00496275
Drug: Vinorelbine plus cisplatin
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01446484
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Trial: NCT01446484
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
Trial: NCT01446484
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Trial: NCT02218879
Drug: Tecfidera
RxNorm normalized name: Tecfidera
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tecfidera 240 mg bid
Trial: NCT00724464
Drug: Rebetol (ribavirin)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
Trial: NCT03455322
Drug: norepinephrine versus midodrine & octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
Trial: NCT00496275
Drug: Gemcitabine plus cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00545961
Drug: amoxicillin clavulanate acid
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mixture 0.28125 ml / kg twice a day for 7 days
Trial: NCT02144922
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: statin
Trial: NCT02978443
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
Trial: NCT02978443
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
Trial: NCT00081302
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00081302
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00446095
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg PO BID
Trial: NCT02012062
Drug: TPF neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02012062
Drug: Concurrent chemotherapy with cisplatin during radiotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02012062
Drug: Concurrent nimotuzumab during radiotherapy
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00717314
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 to 2.0 g daily PO BID
Trial: NCT00117156
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00117156
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01413789
Drug: BAP scar gel
RxNorm normalized name: allantoin Topical Gel [Mederma Advanced Scar]
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 application of BAP scar gel
Trial: NCT04603976
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Trial: NCT00056225
Drug: Folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00056225
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00056225
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04001894
Drug: Ticagrelor 90mg
RxNorm normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
Trial: NCT00661206
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
Trial: NCT01419184
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01419184
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04001894
Drug: Clopidogrel 75mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
Trial: NCT00562289
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: during the follow up
Trial: NCT00562289
Drug: Antivitamins K or rivaroxaban or dabigatran or apixaban
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: during the follow up
Trial: NCT00836537
Drug: Benazepril HCl 40 mg Tablets
RxNorm normalized name: benazepril
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg, single-dose fed
Trial: NCT00908791
Drug: Conjugated Linoleic Acid (CLA)
RxNorm normalized name: linoleic acids, conjugated
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
Trial: NCT03845881
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Trial: NCT02071862
Drug: CBE
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CB-839 in combination with standard dose everolimus
Trial: NCT02071862
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CB-839 in combination with standard dose docetaxel
Trial: NCT01936181
Drug: Remicade (infliximab)
RxNorm normalized name: infliximab Injection [Remicade]
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01936181
Drug: SB2 (proposed biosimilar to infliximab)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00765895
Drug: Nortriptyline Hydrochloride
RxNorm normalized name: Nortriptyline Hydrochloride
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
Trial: NCT00880581
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg injection
Trial: NCT00263328
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT00682643
Drug: fluticasone furoate nasal spray
RxNorm normalized name: fluticasone furoate Metered Dose Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluticasone furoate nasal spray
Trial: NCT01875185
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg orally daily for 7 days
Trial: NCT02726438
Drug: Debio 1450
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
Trial: NCT01171781
Drug: cisplatin (3 weekly)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
Trial: NCT01171781
Drug: cisplatin (weekly)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
Trial: NCT02833948
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Clopidogrel 75 mg OD for first 90 days
Trial: NCT02833948
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)
Trial: NCT02588521
Drug: AL-794
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03388957
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug will be given before the extraction procedure
Trial: NCT03388957
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This drug will be given before the extraction procedure
Trial: NCT03360006
Drug: ABBV-744
RxNorm normalized name: ABBV-744
DrugBank: ABBV-744 (DB19199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral
Trial: NCT04044222
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT04044222
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT04044222
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00110890
Drug: cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
Trial: NCT00887276
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days
Trial: NCT03860129
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A: Isoflurane (0.5 MAC)
Trial: NCT03860129
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B: Sevoflurane (0.5 MAC)
Trial: NCT03860129
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group C: Desflurane (0.5 MAC)
Trial: NCT00970632
Drug: Tadalafil 5 mg
RxNorm normalized name: tadalafil 5 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg po QD for 12 weeks
Trial: NCT00970632
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg po QD for 12 weeks
Trial: NCT01930188
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Trial: NCT01930188
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Trial: NCT01068977
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Repeating intravenous dose
Trial: NCT01068977
Drug: MetMAb
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeating escalating intravenous dose
Trial: NCT01068977
Drug: MetMAb
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeating intravenous dose
Trial: NCT01187888
Drug: Rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet once daily 1 mg 1 year
Trial: NCT01187888
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet once daily one year
Trial: NCT02170207
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg injection
Trial: NCT03780465
Drug: Oral idronoxil suspension
RxNorm normalized name: Idronoxil
DrugBank: Idronoxil (DB04915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
Trial: NCT00348595
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
Trial: NCT01943851
Drug: GSK525762
RxNorm normalized name: Bet inhibitor gsk525762
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
Trial: NCT00694252
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
Trial: NCT00330330
Drug: ISIS 113715
RxNorm normalized name: ISIS 113715
DrugBank: ISIS 113715 (DB05506)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00887276
Drug: Ampicillin;Amoxicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days
Trial: NCT00031681
Drug: 7-hydroxystaurosporine
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00031681
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02588716
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
Trial: NCT00180128
Drug: all-trans retinoid acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00180128
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00180128
Drug: mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00180128
Drug: daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00180128
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01990196
Drug: degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.
Trial: NCT01990196
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.